These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 25777467)

  • 1. Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.
    Nishio M; Horiike A; Nokihara H; Horinouchi H; Nakamichi S; Wakui H; Ohyanagi F; Kudo K; Yanagitani N; Takahashi S; Kuboki Y; Yamamoto N; Yamada Y; Abe M; Tahata T; Tamura T
    Invest New Drugs; 2015 Jun; 33(3):632-40. PubMed ID: 25777467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
    Spigel DR; Edelman MJ; O'Byrne K; Paz-Ares L; Mocci S; Phan S; Shames DS; Smith D; Yu W; Paton VE; Mok T
    J Clin Oncol; 2017 Feb; 35(4):412-420. PubMed ID: 27937096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
    Spigel DR; Ervin TJ; Ramlau RA; Daniel DB; Goldschmidt JH; Blumenschein GR; Krzakowski MJ; Robinet G; Godbert B; Barlesi F; Govindan R; Patel T; Orlov SV; Wertheim MS; Yu W; Zha J; Yauch RL; Patel PH; Phan SC; Peterson AC
    J Clin Oncol; 2013 Nov; 31(32):4105-14. PubMed ID: 24101053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.
    Kishi K; Sakai H; Seto T; Kozuki T; Nishio M; Imamura F; Nokihara H; Satouchi M; Nakagawa S; Tahata T; Nakagawa K
    Cancer Treat Res Commun; 2019; 18():100113. PubMed ID: 30472556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.
    Xin Y; Jin D; Eppler S; Damico-Beyer LA; Joshi A; Davis JD; Kaur S; Nijem I; Bothos J; Peterson A; Patel P; Bai S
    J Clin Pharmacol; 2013 Nov; 53(11):1103-11. PubMed ID: 23922054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.
    Penuel E; Li C; Parab V; Burton L; Cowan KJ; Merchant M; Yauch RL; Patel P; Peterson A; Hampton GM; Lackner MR; Hegde PS
    Mol Cancer Ther; 2013 Jun; 12(6):1122-30. PubMed ID: 23536720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer.
    Han K; Chanu P; Jonsson F; Winter H; Bruno R; Jin J; Stroh M
    AAPS J; 2017 Mar; 19(2):527-533. PubMed ID: 28028730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
    Yoh K; Doi T; Ohmatsu H; Kojima T; Takahashi H; Zenke Y; Wacheck V; Enatsu S; Nakamura T; Turner K; Uenaka K
    Invest New Drugs; 2016 Oct; 34(5):584-95. PubMed ID: 27422720
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Pool M; Terwisscha van Scheltinga AGT; Kol A; Giesen D; de Vries EGE; Lub-de Hooge MN
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1328-1336. PubMed ID: 28315949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
    Wakelee H; Zvirbule Z; De Braud F; Kingsley CD; Mekhail T; Lowe T; Schütte W; Lena H; Lawler W; Braiteh F; Cosgriff T; Kaen D; Boyer M; Hsu J; Phan S; Novello S
    Clin Lung Cancer; 2017 Jan; 18(1):50-59. PubMed ID: 27856142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of onartuzumab in patients with solid cancers: A meta-analysis of randomized trials.
    Kim BJ; Kim D; Kim JH; Kim HS; Jang HJ
    Indian J Cancer; 2021; 58(2):232-240. PubMed ID: 33402588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
    Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
    J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.
    Koeppen H; Yu W; Zha J; Pandita A; Penuel E; Rangell L; Raja R; Mohan S; Patel R; Desai R; Fu L; Do A; Parab V; Xia X; Januario T; Louie SG; Filvaroff E; Shames DS; Wistuba I; Lipkind M; Huang J; Lazarov M; Ramakrishnan V; Amler L; Phan SC; Patel P; Peterson A; Yauch RL
    Clin Cancer Res; 2014 Sep; 20(17):4488-98. PubMed ID: 24687921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer.
    Hirsch FR; Govindan R; Zvirbule Z; Braiteh F; Rittmeyer A; Belda-Iniesta C; Isla D; Cosgriff T; Boyer M; Ueda M; Phan S; Gandara DR
    Clin Lung Cancer; 2017 Jan; 18(1):43-49. PubMed ID: 27461773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
    Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
    Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
    Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
    Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
    Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
    Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
    Yamamoto N; Murakami H; Hayashi H; Fujisaka Y; Hirashima T; Takeda K; Satouchi M; Miyoshi K; Akinaga S; Takahashi T; Nakagawa K
    Br J Cancer; 2013 Nov; 109(11):2803-9. PubMed ID: 24169346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.
    Rosen LS; Goldman JW; Algazi AP; Turner PK; Moser B; Hu T; Wang XA; Tuttle J; Wacheck V; Wooldridge JE; Banck M
    Clin Cancer Res; 2017 Apr; 23(8):1910-1919. PubMed ID: 27803065
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.